Plasma interleukin-6 and fatigue in terminally ill cancer patients
Plasma interleukin-6 and fatigue in terminally ill cancer patients
复制标题
DOI：
10.1016/j.jpainsymman.2007.03.009
复制
发表时间：
2008-02-01
影响因子：
4.7
通讯作者：
Uchitomi, Yosuke
中科院分区：
文献类型：
--
作者：
Inagaki, Masatoshi;Isono, Masako;Uchitomi, Yosuke
疲劳是癌症晚期患者最令人痛苦的症状之一。然而，尚未采取有效的干预措施。几项研究表明，细胞因子在接受抗癌治疗的癌症患者、转移性癌症患者和癌症幸存者中的疲劳中发挥作用，但在晚期癌症患者中则不然。在本研究中，疲劳和血浆白细胞介素-6（IL-6）之间的潜在关联在46例晚期癌症患者（中位生存期：64.5天）中进行了检查，这些患者既没有接受类固醇也没有接受非甾体抗炎药。通过癌症疲劳量表（CFS）评估疲劳，该量表由疲劳的多个维度组成，如身体，情感和认知子量表。采用酶联免疫吸附测定法测定血浆IL-6水平，并将CFS总分定义的有无“临床疲劳”患者进行比较。此外，还检查了CFS评分和IL-6水平之间的相关性。因此，临床疲劳患者的IL-6水平（n = 27 [59%];平均值、SD、中位数和范围：分别为37.1、46.4、17.1和3.7-182.5 pg/ml）显著高于无临床疲劳的患者（n = 19 [41%];平均值、SD、中位数、范围：分别为14.3、12.2、8.0和2.8-45.0 pg/ml）（P = 0.02）。IL-6水平与躯体症状评分显著相关（r = 0.35，P = 0.02），与其他量表评分无相关性。总之，IL-6可能在晚期癌症患者的疲劳中发挥作用，特别是在身体方面。本研究的结果提供了信息，以开发一种新的治疗策略，癌症疲劳的晚期癌症患者。
Fatigue is one of the most distressing symptoms among terminally ill cancer patients. However, no effective intervention has been established. Several studies have suggested the role of cytokines in fatigue in cancer patients receiving anti-cancer treatment, patients with metastatic cancer, and cancer survivors, but not in terminally ill cancer patients. In the present study, the potential association between fatigue and plasma interleukin-6 (IL-6) was examined in 46 terminally ill cancer patients (median survival: 64.5 days) who received neither steroids nor nonsteroidal anti-inflammatory drugs. Fatigue was evaluated by the Cancer Fatigue Scale (CFS), which consists of multiple dimensions of fatigue, such as Physical, Affective, and Cognitive subscales. Plasma IL-6 levels were measured using an enzyme-linked immunosorbent assay and were compared between patients with and without "clinical fatigue" as defined by the total score of the CFS. Additionally, associations between each of the CFS scores and IL-6 levels were examined. As a result, the IL-6 level in patients with clinical fatigue (n = 27 [59%]; mean, SD, median, and range: 37.1, 46.4, 17.1, and 3.7-182.5 pg/ml, respectively) was significantly higher than those without clinical fatigue (n = 19 [41%]; mean, SD, median, range: 14.3, 12.2, 8.0, and 2.8-45.0 pg/ml, respectively) (P = 0.02). The IL-6 level significantly correlated with the Physical subscale score (r = 0.35, P = 0.02), but not with other subscale scores. In conclusion, IL-6 may play a role in fatigue, especially in the physical dimension, in terminally ill cancer patients. The results of the present study provide information to develop a new treatment strategy for cancer fatigue in terminally ill cancer patients.